MedTrace Logo

Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds

NCT02602184 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-07-19

No results posted yet for this study

Summary

This clinical study will be a prospective, placebo-controlled, double-blind, randomized and centrally evaluated intra-individual comparative study to assess the safety and efficacy of AR/101 concomitantly administered with Standard of Care (SoC) in accelerating re epithelialization of split thickness wounds compared with placebo and concomitantly with SoC, in the pannus of volunteers undergoing elective abdominoplasty.

Conditions

  • Wounds and Injuries

Interventions

DRUG

AR/101

DRUG

Placebo

Sponsors & Collaborators

  • Cato Research

    collaborator INDUSTRY

  • Arava Bio Tech Ltd.

    lead INDUSTRY

Principal Investigators

  • Robert Galiano, MD FACS · Northwestern University Feinberg School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02602184 on ClinicalTrials.gov